Pharmaceuticals APAC

APAC Liver Cirrhosis Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Liver Cirrhosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Cause, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.50 Bn Placeholder estimate
Estimate 2025 $2.65 Bn 21.9% of the global market
Projected 2034 $4.44 Bn 67.5% Adds $1.79 Bn over 9 forecast years
CAGR 2025–2034 5.9% Faster than 13% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 21.86% of the global market.
  • Among regions, the largest is North America at $5.54 Bn.
  • Fastest growing: Africa at 6.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.79 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Liver Cirrhosis Treatment Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.50 Bn — —
2025 (base) $2.65 Bn +$147.7 Mn —
2026 (forecast) $2.81 Bn +$156.4 Mn +5.9%
2027 (forecast) $2.97 Bn +$165.6 Mn +12.1%
2028 (forecast) $3.15 Bn +$175.4 Mn +18.8%
2029 (forecast) $3.33 Bn +$185.7 Mn +25.8%
2030 (forecast) $3.53 Bn +$196.7 Mn +33.2%
2031 (forecast) $3.74 Bn +$208.3 Mn +41.1%
2032 (forecast) $3.96 Bn +$220.6 Mn +49.4%
2033 (forecast) $4.19 Bn +$233.6 Mn +58.2%
2034 (forecast) $4.44 Bn +$247.4 Mn +67.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Liver Cirrhosis Treatment Market Analysis at a glance
Market size, 2025$2.65 Bn placeholder estimate
Forecast, 2034$4.44 Bn placeholder estimate
Growth (CAGR), 2025–20345.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, cause and end user (see all)
Key playersSalix (Bausch Health), Gilead Sciences, Inc., Madrigal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Novo Nordisk A/S (see all)
Active clinical trials195 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Liver Cirrhosis Treatment Market Analysis Executive Summary

Liver cirrhosis treatments manage scarring of the liver and its complications such as fluid build-up and confusion.

Key segments of the liver Cirrhosis Treatment market include treatment (Medications, Liver Transplant and Nutrition Support) and cause (Alcohol-Related, MASH-Related and Viral Hepatitis).

Bar chart: Asia Pacific Liver Cirrhosis Treatment market size, 2024–2034, placeholder estimates. $2.50 Bn in 2024, $2.65 Bn in 2025 and $4.44 Bn in 2034, 5.9% CAGR.
Asia Pacific Liver Cirrhosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Liver Cirrhosis Treatment Market Dynamics

Market Growth Drivers

Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the liver Cirrhosis Treatment market.

Opportunity

Microbiome-based treatments, earlier testing and digital gut-health programmes give the liver Cirrhosis Treatment market room to grow.

Market Restraints

Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the liver Cirrhosis Treatment market.

Competitive Landscape for Liver Cirrhosis Treatment Market in APAC

The liver Cirrhosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Liver Cirrhosis Treatment Market in APAC

Liver Cirrhosis Treatment in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 195 studies on Liver Cirrhosis Treatment that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for liver Cirrhosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Liver Cirrhosis Treatment right now, from free public sources.

Clinical trials

195 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Ipsen 6 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Zydus Lifesciences 5 active trials on ClinicalTrials.gov (opens in a new tab)
  3. GSK PLC 5 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Gilead Sciences, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Regeneron Pharmaceuticals 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 4,837 papers since 2021 (worldwide)

  1. Pleural empyema and perisplenic abscess caused by Clostridioides difficile in a patient with liver cirrhosis and previous C. difficile colitis: a case report. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026
  2. Recent recommendations for the diagnosis and management of liver cirrhosis and its complications. Expert review of gastroenterology & hepatology, 2026
  3. [Alcoholic Myopathy]. Brain and nerve = Shinkei kenkyu no shinpo, 2026
  4. Total glucosides of paeony in cirrhosis: mechanisms of action via the gut-liver axis - a review. Frontiers in gastroenterology (Lausanne, Switzerland), 2026
  5. Hepatic Erbin loss promotes CCl(4)-induced liver fibrosis by potentiating the TGF-β/Smad signaling in hepatocytes. Toxicology letters, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Liver Cirrhosis Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Liver Cirrhosis Treatment market in Asia Pacific?
Placeholder estimate: about $2.65 Bn in 2025, rising to about $4.44 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Liver Cirrhosis Treatment market in Asia Pacific growing?
Placeholder estimate: about 5.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Liver Cirrhosis Treatment market report cover?
The report splits the market by treatment (Medications, Liver Transplant, Nutrition Support), cause (Alcohol-Related, MASH-Related, Viral Hepatitis) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Liver Cirrhosis Treatment market?
Key players include Salix (Bausch Health), Gilead Sciences, Inc., Madrigal Pharmaceuticals, Mallinckrodt Pharmaceuticals and Novo Nordisk A/S.
What is driving the Liver Cirrhosis Treatment market?
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the liver Cirrhosis Treatment market.
How many clinical trials on Liver Cirrhosis Treatment are running in Asia Pacific?
195 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Liver Cirrhosis Treatment?
PubMed lists 4,837 papers on Liver Cirrhosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on liver health and alcohol

See the topic